H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities climb as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts RAPT Hot Sheet
Price: $58.02 --0%
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 41
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 41
Join SI Premium – FREE
H.C. Wainwright analyst Emily Bodnar downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral with a price target of $58.00.
For an analyst ratings summary and ratings history on Rapt Therapeutics click here. For more ratings news on Rapt Therapeutics click here.
Shares of Rapt Therapeutics closed at $35.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Downgrades Aardvark Therapeutics Inc (AARD) to Perform 'We Await Visibility'
- Avalo Therapeutics Inc. (AVTX) PT Lowered to $16 at Oppenheimer
- Evercore ISI Reiterates Outperform Rating on Reddit (RDDT)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
